

PRESS RELEASE · JUNE 15, 2026

Lotus Neuro Appoints Junghae Suh PhD as Chief Technology Officer

Gene-therapy delivery pioneer to lead technology development for the company's focused-ultrasound neuro-therapeutics platform.

BOSTON, MASS., JUNE 15, 2026 - Lotus Neuro, a clinical-stage neuro-therapeutics company combining precision focused ultrasound (FUS) with advanced medicines to treat brain disease, today announced the appointment of Junghae Suh PhD as Chief Technology Officer. Dr. Suh will lead the continued development of the company's programmable delivery platform, advancing the technology that enables measurable, controllable therapeutic effects across the blood-brain barrier.

Dr. Suh is a bioengineer and recognized leader in gene-therapy innovation, with deep expertise in designing advanced delivery systems for complex disease. She previously served as Vice President and Head of Biogen's Gene Therapy Accelerator Unit, where she led efforts to develop transformative therapies for neurological disorders. Prior to Biogen, she was a tenured professor at Rice University, where her pioneering work in synthetic virology focused on engineering viruses as programmable platforms for targeted gene delivery. She is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

As Chief Technology Officer, Dr. Suh will oversee platform engineering, delivery science, and the technical roadmap that underpins Lotus Neuro's neuro-oncology programs, bringing a rare combination of scientific rigor and translational leadership to the company's mission.



"Junghae has spent her career solving the hardest problem in neuroscience, getting therapies precisely where they need to go. Her vision for programmable delivery is exactly what our platform was built to realize, and her leadership will accelerate everything we do."

ARJUN "JJ" DESAI, MD · FOUNDER & CHIEF EXECUTIVE OFFICER, LOTUS NEURO

"Lotus Neuro is pursuing a fundamentally new way to reach the brain, one that pairs the precision of focused ultrasound with the power of modern medicines. The opportunity to build delivery technology that is measurable, repeatable, and scalable is what drew me here."

JUNGHAE SUH PHD · CHIEF TECHNOLOGY OFFICER, LOTUS NEURO

Dr. Suh's appointment reflects Lotus Neuro's continued investment in the scientific and technical leadership needed to translate breakthrough delivery science into therapies for patients with complex neurological disease.

ABOUT LOTUS NEURO

Lotus Neuro is a clinical-stage neuro-therapeutics company working to bring effective medicine to the brain. The same barrier that protects the brain also blocks most therapeutics from reaching a tumor at meaningful levels. By pairing precision focused ultrasound with neuro-therapeutics, Lotus Neuro is building a programmable, non-invasive platform designed to enable measurable and controllable therapeutic effects in the brain, starting in neuro-oncology and built to scale across modalities and neurological disease over time.

MEDIA CONTACT

Lotus Neuro Communications

press@lotusneuro.com

This press release contains forward-looking statements about Lotus Neuro, Inc.'s technology and development plans that are subject to risks and uncertainties, and actual results may differ. Lotus Neuro's technology is investigational and has not been cleared or approved by the FDA.

###